Therapeutic effects of a new quinolone, DU-6859a, on polymicrobial infections in a newly designed model of rat uterine endometritis

Journal of Antimicrobial Chemotherapy

Volumn 41, Issue 1, 1998, Pages 131-133

  Mikamo, Hiroshige ^a   Kawazoe, Kyoko ^a   Sato, Yasumasa ^a   Izumi, Koji ^a   Tamaya, Teruhiko ^a  

^a GIFU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOFLOXACIN; QUINOLONE; SITAFLOXACIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COUNT; BACTERIAL INFECTION; BACTEROIDES FRAGILIS; CONTROLLED STUDY; DRUG EFFICACY; ENDOMETRITIS; ESCHERICHIA COLI; FEMALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT;

ANIMALS; ANTI-INFECTIVE AGENTS; BACTEROIDES FRAGILIS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; ENDOMETRITIS; ESCHERICHIA COLI; FEMALE; FLUOROQUINOLONES; OFLOXACIN; QUINOLONES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0031908761     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/41.1.131     Document Type: Article

References (10)

1. Wolfson, J. S. & Hooper, D. C. (1992). The fluoroquinolones: clinical and laboratory considerations. Clinical Microbiology Newsletter 14, 1-7.
2. Hoshino, K., Sato, K., Kitamura, A., Hayakawa, I., Sato, M. & Osada, Y. (1991). Inhibitory effects of DU-6859a, a new fluoroquinolone, on bacterial DNA gyrase and topoisomerase II. In Program and Abstracts of the Thirty-First Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 1991. Abstract 1506, p. 350. American Society for Microbiology, Washington, DC.
3. Sato, K., Hoshino, K., Tanaka, M., Hayakawa, I. & Osada, Y. (1992). Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates. Antimicrobial Agents and Chemotherapy 36, 1491-8.
4. Marshall, S. A. & Jones, R. N. (1993). In vitro activity of DU-68593, a new fluorocyclopropyl quinolone. Antimicrobial Agents and Chemotherapy 37, 2747-53.
5. Mikamo, H., Ito, K. & Tamaya, T. (1994). Studies on the clinical implication of anaerobes, especially Prevotella bivia in obstetrics and gynecology. Acta Scholae Medicinalis Universitatis in Gifu 42, 230-48.
6. National Committee for Clinical Laboratory Standards. (1990). Methods for Dilution Antimicrobial Susceptibility Testing for Bacteria that Grow Aerobically - Second Edition. Approved Standard M7-A2. NCCLS, Villanova, PA.
7. National Committee for Clinical Laboratory Standards. (1990). Methods for Dilution Antimicrobial Susceptibility Testing of Anaerobic Bacteria - Second Edition. Approved Standard M11-A2. NCCLS, Villanova, PA.
8. Nakashima, M., Kosuge, K., Uematsu, K., Takiguchi, Y., Kondo, K., Mizuno, A. et al. (1995). Clinical pharmacology of antimicrobial pyridonecarboxylic acids. (III) Comparative study of newly developed compounds on pharmacokinetics in healthy humans. Japanese Journal of Chemotherapy 43, 647-54.
9. Nakashima, M., Uematsu, T., Kosuge, K., Umemura, K., Hakusui, H. & Tanaka, M. (1995). Pharmacokinetics and tolerance of DU-6859a, a new fluoroquinolone, after single and multiple oral doses in healthy volunteers. Antimicrobial Agents and Chemotherapy 39, 170-4.
10. Okada, J. (1983). Experimental model for genital tract infection due to anaerobic bacteria. Proceedings of the 13th Meeting of the Japanese Association for Anaerobic Infection Research 13, 172-82.